MTN-017: A rectal phase 2 extended safety and acceptability study of tenofovir reduced-glycerin 1% gel

• Main Authors: Ross D. Cranston, Javier R. Lama, Barbra A. Richardson, Alex Carballo-Diéguez, Ratiya Pamela Kunjara Na Ayudhya, Karen Liu, Karen B. Patterson, Cheng Shiun Leu, Beth Galaska, Cindy E. Jacobson, Urvi M. Parikh, Mark A. Marzinke, Craig W. Hendrix, Sherri Johnson, Jeanna M. Piper, Cynthia Grossman, Ken S. Ho, Jonathan Lucas, Jim Pickett, Linda Gail Bekker, Suwat Chariyalertsak, Anupong Chitwarakorn, Pedro Gonzales, Timothy H. Holtz, Albert Y. Liu, Kenneth H. Mayer, Carmen Zorrilla, Jill L. Schwartz, James Rooney, Ian McGowan
• Format: Journal
• Published: 2018
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85018192380&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/47352
• Institution: Chiang Mai University

© The Author 2017. Background. Human immunodeficiency virus (HIV) disproportionately affects men who have sex with men (MSM) and transgender women (TGW). Safe and acceptable topical HIV prevention methods that target the rectum are needed. Methods. MTN-017 was a phase 2, 3-period, randomized sequenc...